Bargain hunters should focus on biotechs since momentum is clearly on their side. On Wednesday, stocks closed higher, led by the small- and mid-cap sectors. The Nasdaq led all other indices, up 1%, while the S&P 500 rose 0.7% with 7 of 10 sectors advancing, and the Dow industrials gained 0.6%. Retail sales for July were flat, but rather than this being interpreted as a … Continue reading Biotech Stocks Are A Bargain in Today’s Market
Extending its association with Carmel, IN-based software solutions provider – Clinical Architecture, Allscripts Healthcare Solutions, Inc. (MDRX) contracted to integrate the former’s comprehensive terminology management system, Symedical, with its dbMotion interoperability platform to streamline vocabulary mapping. By incorporating Symedical, Allscripts intends to provide its clients with efficient and enhanced mapping tools and improved vocabulary distribution. This would allow the clients to achieve health information exchange … Continue reading Biotech News: Allscripts Healthcare & Clinical Architecture Extend Critical Alliance
International Game Technology IGT reported solid secondquarter results in line with our expectations. Revenue increased 11% to $600 million (compared with consensus of $572 million) and EBITDA increased 6% to $247 million (consensus of $200 million). The increase in revenue was driven by a 16% rise in product sales, primarily due to strong sales of video lottery terminals in Canada, sales to new casinos in … Continue reading International Game Technology Reports Solid 2Q Results; Shares Moderately Undervalued
Jazz Pharmaceuticals (JAZZ) shares climbed 6.97% after the company announced that it has entered into an agreement to acquire the rights to defibrotide from Sigma-Tau Pharmaceuticals, Inc. The deal is expected to close in the third quarter of 2014. Sigma-Tau held the rights to defibrotide on the basis of an agreement with Gentium, which was acquired by Jazz Pharma earlier this year. Jazz Pharma markets … Continue reading Biotech Stock News: Jazz Pharma Shares Go Up Due to Defibrotide Buy
We are maintaining our fair value estimate and economic moat rating for Ingram Micro IM after the company reported solid first-quarter results that indicated consumers across the globe are spending more on IT. Ingram Micro’s sales grew 19% year-over-year to $10.6 billion, with the 2012 BrightPoints and Aptec acquisitions adding $1.85 billion, or 13%, to the top-line. Organic sales added 6% growth. Encouragingly, the company … Continue reading Ingram Micro Sees More IT Spending Across All Regions
Vertex Pharmaceuticals’ (VRTX) cystic fibrosis (CF) drug, Kalydeco (ivacaftor) won a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for use in CF patients (6 years of age and above) with one of eight non-G551D gating mutations in the cystic fibrosis trans membrane conductance regulator (CFTR) gene. Kalydeco is already approved in the EU for CF patients (6 years of … Continue reading Biotech Stocks Under Focus: Vertex Pharma Captures Headlines
